1 / 11

Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate?.

merton
Download Presentation

Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? Kevin P. Bliden, BS; Joseph DiChiara, BS; Udaya S. Tantry, PhD; Ashwani K. Bassi, MS; Srivasavi K. Chaganti, MD; Paul A. Gurbel, MD Published in JACC February 13, 2007

  2. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Background (cont.) • Platelet aggregation can lead to ischemic complications after percutaneous coronary intervention (PCI). • Dual antiplatelet therapy with aspirin and clopidogrel is the gold standard to attenuate platelet function during PCI. • However, nearly 20% of PCI patients will experience recurrent ischemic or thrombotic events. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  3. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Background (cont.) • The goal of this study was to determine whether patients receiving chronic clopidogrel therapy undergoing nonemergent stenting who display high on-treatment preprocedural platelet aggregation are at increased risk for poststenting ischemic events. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  4. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Study Design 100 patients > 18 yrs receiving clopidogrel for ≥1month before non-emergent PCI. Exclusion criteria: history of bleeding diathesis, acute MI within 48 h, elevated cardiac markers, cerebrovascular event within 3 months, illicit drug or alcohol abuse, prothrombin time >1.5times control, platelet count < 100,000/mm3, hematocrit <30%, creatinine >4.0mg/dl, and glycoprotein (GP) IIb/IIIa use before the procedure. LTA and TEG to determine platelet reactivity Normal On-Treatment Platelet Reactivity (NPR) n=78 Hi On-treatment Platelet Reactivity* (HPR) n=22 1, 6, and 12 mos. follow-up • Primary Endpoint: Ischemic events defined as: death secondary to any cardiovascular cause, stroke, myocardial infarction, ischemia requiring a hospital stay, and target vessel revascularization (TVR), nontarget vessel revascularization (NTVR), or medical management. *HPR defined as ≥ 50% ADP-induced aggregation after stimulation with 5-μmol ADP as measured by LTA or ≥ 70% ADP-platelet induced aggregation with 2-μmol ADP as measured by TEG. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  5. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Baseline Characteristics • Cardiovascular risk factors and multivessel interventions using drug-eluting stents were common. • No significant differences in age, gender, ethnicity, BMI, baseline medications, or hematological data existed between reactivity groups. • Patients with HPR exhibited a higher prevalence of hypertension, diabetes, and use of calcium-channel blockers. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  6. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Results Baseline on-treatment Aggregation in Patients with and without Ischemic Events As measured by LTA As measured by TEG 76±13% p < 0.0001 p < 0.0001 Baseline on-treatment aggregation Baseline on-treatment aggregation 50±13% 49±13% 31±13% n = 23 n = 77 n = 23 n = 77 With Events Without Events With Events Without Events Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  7. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Results (cont.) Percentage of Patients with and without Ischemic Events Displaying HPR at Baseline As measured by LTA As measured by TEG 87% 70% Displaying HPR (%) Displaying HPR (%) 17% 8% n = 23 n = 77 n = 23 n = 77 With Events With Events Without Events Without Events Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  8. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Results (cont.) • These results yielded positive predictive values of 73% and 67% and negative predictive values of 91% and 94%, respectively, for the LTA and TEG, and demonstrating 87% test efficiency with the LTA and 85% test efficiency with the TEG. • The area under the combined receiver-operating characteristic (ROC) curve showed that LTA and TEG can distinguish between ischemic and nonischemic groups (area=0.862, p=0.0001 for LTA, area=0.881, p=0.0001 for TEG). Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  9. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Results (cont.) • High on-treatment platelet reactivity as measured by aggregometry and TEG were the only variables significantly related to ischemic events (p<0.0001 for both assays). • The administration of eptifibatide reduced periprocedural elevation in platelet reactivity, with no significant differences in bleeding events. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  10. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Limitations • The results are limited by a small sample size. • Patients were not given an additional loading does of clopidogrel. The clinical benefit of reloading patients already treated with chronic clopidogrel therapy with a further 300- or 600-mg dose remains unclear. • Inherent differences within the study population by virtue of their need for repeat PCI could have impacted the prevalence of high platelet reactivity. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

  11. Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing PCI: Summary • Patients receiving chronic clopidogrel therapy undergoing nonemergent PCI, who exhibit high on-treatment ADP-induced platelet aggregation by LTA or TEG, are at increased risk for postprocedural ischemic events. • The results of the study have potential implications for clinicians who do not administer additional clopidogrel (before or after PCI) to patients receiving chronic clopidogrel therapy. Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

More Related